China's Drug Regulators Issue Warning On Use Of Avandia While Debating Suspension Vs. Restricted Use
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's State FDA issued a warning Sept. 25 on the potential cardiovascular risk of using drugs containing rosiglitazone and told the public that the agency is organizing a committee of experts to evaluate the benefits and risks of rosiglitazone drugs, including GlaxoSmithKline's Avandia (rosiglitazone), Avandamet (metformin and rosiglitazone) and generics
You may also be interested in...
As More Leading Doctors Oppose Avandia, Will Indian Regulators Propose A Ban?
MUMBAI - Leading Indian doctors have begun speaking out against GlaxoSmithKline's anti-diabetes brand Avandia (rosiglitazone) - branded as Windia in the Indian market - after U.S.FDA restricted the drug's use and European regulatory authorities ordered a complete withdrawal of the medicine from the market
Like U.S. Counterparts, South Korea FDA Regulators Move To Severely Restrict Use Of Diabetes Treatments Including GSK's Avandia
SEOUL - Following a U.S. FDA action to drastically limit the use of diabetes treatments containing rosiglitazone, Korea FDA is adopting similar measures, advising doctors and patients not to use 15 of these medicines available locally including GlaxoSmithKline's Avandia
GSK Will End Avandia Promotion Worldwide
Even in countries where the drug will still be sold, the firm projects "minimal" sales.